ChemicalBook > CAS DataBase List > GDC-0994 (hydrochloride)

GDC-0994 (hydrochloride)

Product Name
GDC-0994 (hydrochloride)
CAS No.
2070009-58-2
Chemical Name
GDC-0994 (hydrochloride)
Synonyms
CS-2072;GDC-0994 HCl;GDC-0994 (hydrochloride);Ravoxertinib hydrochloride;Ravoxertinib hydrochloride (GDC-0994;RAVOXERTINIB HYDROCHLORIDE (GDC-0994 HYDROCHLORIDE)
CBNumber
CB73048653
Molecular Formula
C21H19Cl2FN6O2
Formula Weight
477.32
MOL File
2070009-58-2.mol
More
Less

GDC-0994 (hydrochloride) Property

storage temp. 
Store at -20°C
solubility 
DMSO: 100 mg/mL (209.50 mM)
form 
Solid
color 
Light yellow to yellow
More
Less

Safety

HS Code 
2924297099
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

ChemScene
Product number
CS-5092
Product name
Ravoxertinibhydrochloride
Purity
98.99%
Packaging
5mg
Price
$96
Updated
2021/12/16
ChemScene
Product number
CS-5092
Product name
Ravoxertinibhydrochloride
Purity
98.99%
Packaging
10mg
Price
$120
Updated
2021/12/16
ChemScene
Product number
CS-5092
Product name
Ravoxertinibhydrochloride
Purity
98.99%
Packaging
50mg
Price
$360
Updated
2021/12/16
More
Less

GDC-0994 (hydrochloride) Chemical Properties,Usage,Production

Uses

Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally bioavailable inhibitor selective for ERK kinase activity with IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.

in vivo

In CD-1 mice, a 10 mg/kg oral dose of Ravoxertinib is sufficient to achieve the desired target coverage for at least 8 h[1]. Daily, oral dosing of Ravoxertinib results in significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice[2].

IC 50

ERK2: 3.1 nM (IC50); ERK1: 6.1 nM (IC50); p-RSK: 12 nM (IC50)

References

[1] Blake JF, et al. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Developme DOI:10.1021/acs.jmedchem.6b00389
[2] Kirk Robarge, et al. Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development. Proceedings: AACR Annual Meeting 2014; April 5-9, 2014.
[3] MICHAEL LAI. Opportunity for Pharmaceutical Intervention in Lung Cancer: Selective Inhibition of JAK1/2 to Eliminate EMT-Derived Mesenchymal Cells.

GDC-0994 (hydrochloride) Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

GDC-0994 (hydrochloride) Suppliers

China 25 United States 5 Global 30
Musechem
Tel
+1-800-259-7612
Fax
+1-800-259-7612
Email
info@musechem.com
Country
United States
ProdList
4660
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
Country
United States
ProdList
32435
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
Cckinase, Inc.
Tel
+1 (732)236-3202
Email
sales@cckinase.com
Country
United States
ProdList
2738
Advantage
58
MedChemExpress
Tel
--
Fax
--
Email
sales@medchemexpress.com
Country
United States
ProdList
6398
Advantage
58

2070009-58-2, GDC-0994 (hydrochloride)Related Search:


  • GDC-0994 (hydrochloride)
  • GDC-0994 HCl
  • CS-2072
  • Ravoxertinib hydrochloride
  • RAVOXERTINIB HYDROCHLORIDE (GDC-0994 HYDROCHLORIDE)
  • Ravoxertinib hydrochloride (GDC-0994
  • 2070009-58-2